TI
KPTI icon

Trexquant Investment’s Karyopharm Therapeutics KPTI Stock Holding History

Trexquant Investment’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
257,903
+216,170
+518% +$1.65M 0.01% 1112
2025
Q4 		$307K Buy
+41,733
New +$255K ﹤0.01% 1449
2022
Q4 		– Sell
-7,968
Closed -$653K – 1562
2022
Q3 		$653K Buy
7,968
+1,559
+24% +$116K 0.02% 698
2022
Q2 		$434K Buy
6,409
+4,468
+230% +$410K 0.02% 910
2022
Q1 		$215K Sell
1,941
-12,784
-87% -$1.59M 0.01% 1170
2021
Q4 		$1.42M Buy
14,725
+12,312
+510% +$1.23M 0.09% 291
2021
Q3 		$211K Buy
2,413
+777
+47% +$80.7K 0.02% 934
2021
Q2 		$253K Sell
1,636
-641
-28% -$93K 0.02% 796
2021
Q1 		$359K Sell
2,277
-150
-6% -$31.6K 0.03% 667
2020
Q4 		$563K Buy
+2,427
New +$562K 0.06% 401
2020
Q3 		– Sell
-2,843
Closed -$808K – 1383
2020
Q2 		$808K Buy
+2,843
New +$841K 0.06% 480
2019
Q3 		– Sell
-1,127
Closed -$101K – 989
2019
Q2 		$101K Sell
1,127
-539
-32% -$43.3K 0.01% 745
2019
Q1 		$146K Buy
+1,666
New +$185K 0.01% 906
2018
Q3 		– Sell
-783
Closed -$200K – 1074
2018
Q2 		$200K Sell
783
-1,285
-62% -$318K 0.01% 791
2018
Q1 		$416K Buy
+2,068
New +$412K 0.03% 696
2017
Q3 		– Sell
-1,490
Closed -$202K – 911
2017
Q2 		$202K Buy
+1,490
New +$221K 0.06% 668
2017
Q1 		– Sell
-1,934
Closed -$273K – 1202
2016
Q4 		$273K Buy
+1,934
New +$261K 0.04% 687
2016
Q1 		– Sell
-2,660
Closed -$529K – 1050
2015
Q4 		$529K Buy
+2,660
New +$576K 0.05% 660

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Trexquant Investment's KPTI Position: Q1 2026 in Review

Trexquant Investment increased its Karyopharm Therapeutics (KPTI) stake by 518% in Q1 2026, buying an estimated $1.65M and bringing the position to 257,903 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #1112.

Trexquant Investment first reported a position in KPTI in Q4 2015 and has held it in 18 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Trexquant Investment held 257,903 shares of Karyopharm Therapeutics worth $1.44M as of Q1 2026.
  • Trexquant Investment bought 216,170 Karyopharm Therapeutics shares in Q1 2026, an estimated $1.65M.
  • Karyopharm Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q1 2026, its #1112 holding.
  • Trexquant Investment first reported a position in Karyopharm Therapeutics in Q4 2015 and has held it in 18 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.